Chemotherapy for Malignant Gliomas Based on Histoculture Drug Response Assay : A Pilot Study.
10.3340/jkns.2011.50.5.426
- Author:
Ho Shin GWAK
1
;
Hyeon Jin PARK
;
Heon YOO
;
Sang Min YOUN
;
Chang Hun RHEE
;
Seung Hoon LEE
Author Information
1. Department of Neuro-Oncology Clinic, National Cancer Center, Goyang, Korea. nslsh@ncc.re.kr
- Publication Type:Clinical Trial ; In Vitro ; Original Article
- Keywords:
Chemotherapy;
Drug sensitivity tests;
Malignant glioma
- MeSH:
Disease-Free Survival;
Gelatin Sponge, Absorbable;
Glioblastoma;
Glioma;
Humans;
Magnetic Resonance Spectroscopy;
Neoplasm, Residual;
Pilot Projects;
Sensitivity and Specificity
- From:Journal of Korean Neurosurgical Society
2011;50(5):426-433
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: The Histoculture Drug Response Assay (HDRA), which measures chemosensitivity using minced tumor tissue on drug-soaked gelfoam, has been expected to overcome the limitations of in vitro chemosensitivity test in part. We analyzed interim results of HDRA in malignant gliomas to see if the test can deserve further clinical trials. METHODS: Thirty-three patients with malignant gliomas were operated and their tumor samples were examined for the chemosensitivity to 10 chosen drugs by HDRA. The most sensitive chemotherapy regimen among those pre-established was chosen based on the number of sensitive drugs or total inhibition rate (IR) of the regimen. The response was evaluated by 3 month magnetic resonance image. RESULTS: Among 13 patients who underwent total resection of the tumor, 12 showed no evidence of disease and one patient revealed progression. The response rate in 20 patients with residual tumors was 55% (3 complete and 8 partial responses). HDRA sensitivity at the cut-off value of more than one sensitive drug in the applied regimen showed a sensitivity of 100%, specificity of 60% and predictability of 70%. Another cut-off value of >80% of total IR revealed a sensitivity of 100%, specificity of 69%, and predictability of 80%. For 12 newly diagnosed glioblastoma patients, median progression-free survival of the HDRA sensitive group was 21 months, while that of the non-sensitive group was 6 months (p=0.07). CONCLUSION: HDRA for malignant glioma was inferred as a feasible method to predict the chemotherapy response. We are encouraged to launch phase 2 clinical trial with chemosensitivity on HDRA.
